Company news

Relmada Therapeutics, Inc. news in 2025

Relmada Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

December 3, 2025

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

November 13, 2025

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

November 7, 2025

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

November 4, 2025

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

November 4, 2025

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

October 7, 2025

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

September 16, 2025

Relmada Therapeutics Issues Mid-Year CEO Letter to Shareholders

September 11, 2025

Relmada Issues Mid-Year CEO Letter to Shareholders

September 10, 2025

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

August 7, 2025

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

July 31, 2025

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

July 15, 2025

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

June 17, 2025

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 8, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

April 28, 2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

April 27, 2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

April 24, 2025

Relmada Therapeutics To Present NDV-01 Data at AUA2025

April 14, 2025

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

March 27, 2025

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

March 26, 2025

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

March 25, 2025

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

February 5, 2025

Calls in 2025

Decks in 2025